Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,660 | -8,297 | -43,241 | -34,005 | -23,332 |
| Depreciation Amortization | 274 | 142 | 699 | 574 | 428 |
| Accounts receivable | 134 | 134 | -507 | -276 | -3 |
| Accounts payable and accrued liabilities | 834 | 624 | -1,902 | -1,133 | -602 |
| Other Working Capital | -212 | -49 | -3,236 | -2,194 | -1,491 |
| Other Operating Activity | 3,083 | 1,022 | 11,472 | 7,175 | 3,566 |
| Operating Cash Flow | $-12,547 | $-6,424 | $-36,715 | $-29,859 | $-21,434 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -22,430 | -25,574 | 21,565 | 23,559 | 20,088 |
| PPE Investments | -4 | N/A | -5 | N/A | N/A |
| Investing Cash Flow | $-22,434 | $-25,574 | $21,560 | $23,559 | $20,088 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 62,158 | 62,140 | 43,806 |
| Financing Cash Flow | $N/A | $N/A | $62,158 | $62,140 | $43,806 |
| Beginning Cash Position | 63,458 | 63,458 | 16,455 | 16,455 | 16,455 |
| End Cash Position | 28,477 | 31,460 | 63,458 | 72,295 | 58,915 |
| Net Cash Flow | $-34,981 | $-31,998 | $47,003 | $55,840 | $42,460 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,547 | -6,424 | -36,715 | -29,859 | -21,434 |
| Capital Expenditure | -4 | N/A | -5 | N/A | N/A |
| Free Cash Flow | -12,551 | -6,424 | -36,720 | -29,859 | -21,434 |